# Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

> **NCT01428492** · PHASE1 · COMPLETED · sponsor: **Novartis** · enrollment: 90 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** GSK2110183
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01428492
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2018-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01428492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01428492, "Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01428492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*